Immunogenicity and Safety of Maternal DTaP Vaccination: The OKINAWA Study.
文献摘要
Objectives Pertussis causes substantial morbidity and mortality in infants. Although maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination is recommended in many Western countries, Tdap is unavailable in Japan, where only diphtheria-tetanus-acellular pertussis (DTaP) vaccine can be administered during pregnancy. We prospectively evaluated the immunogenicity and safety of maternal DTaP vaccination. Methods Ninety-seven vaccinated and 42 unvaccinated pregnant women were enrolled. The vaccinated group received DTaP at 30-32 weeks' gestation. Antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), diphtheria, and tetanus were measured. Results PT and FHA antibody titers increased significantly 4 weeks after vaccination (6.8-fold to 50.0 EU/mL and 11.3-fold to 119.6 EU/mL, respectively). At delivery, maternal and cord blood antibody titers against all antigens were significantly higher in the vaccinated group, with seropositivity rates of 99-100%. Local and systemic adverse reactions occurred in 65% and 25% of mothers, respectively, and were mostly Grade 1. No safety signals were detected regarding pregnancy outcomes or infant health up to 6 months of age in the relatively small study cohort. Conclusions Maternal DTaP vaccination increased antibody levels responses without identified safety concerns, supporting its potential role in preventing infant pertussis.